Abstract
Introduction: Progression of collapse in osteonecrosis of the femoral head (ONFH) is greatly influenced by repair reactions, especially bone resorptive activity. This study was performed to test if systemic alendronate treatment, a potent inhibitor of osteoclast activity, can prevent the development of collapse in ONFH.
Materials and Methods: Daily administration of oral alendronate (5mg/day) was started in 14 hips in 11 patients with ONFH (Alendronate group). At the beginning of the study (3, 6, 12 months), plain radiographs, T1-weighted MR imaging, and biochemical makers of osteoclast activity (N-telopeptide of type-I collagen) and osteoblast activity (Bone-specific alkaline phosphatase), were examined. At 12 months, MR imaging was repeated. Eleven hips in 6 patients with ONFH who did not receive alendronate administration were considered as the control group.
Results: There was no significant difference with respect to gender distribution, etiology factors, initial ARCO stages, and extent of necrosis in the two groups. In the alendronate group, there was an early decrease of osteoclast activity at 3 months, with a decrease to 62% at 12 months, while the decrease of osteoblast activity was smaller with 80% at 12 months. Development of collapse was observed in 4 of the 11 hips (36%) in the control group, and in none of the 14 hips in the alendronate group. There was a significant difference of collapse development between the two groups (p=0.026, Mann-Whitney U-test). Signal change on serial MR images was observed in 5 of 9 hips (56%) in the control group, with only one of 9 hips (11%) in the alendronate group.
Discussion: The low incidence of signal change on serial MR images may reflect the decrease of repair activity in the alendronate group. The present study was the first clinical trial to show that alendronate has a significant preventive effect of collapse development in patients with osteonecrosis of the femoral head.
The abstracts were prepared by Michael A. Mont, M.D. and Lynne C. Jones, Ph.D. Correspondence should be addressed to L. Jones at Good Samaritan Prof. Bldg., Suite 201, 5601 Loch Raven Blvd., Baltimore, MD 21239
